Hypertension prevalence, awareness, treatment and control in the over 50s in Ireland: evidence from The Irish Longitudinal Study on Ageing

Murphy, Catríona; Kearney, Patricia M.; Shelley, Emer; Fahey, Tom; Dooley, Cara; Kenny, Rose Anne

doi:10.1093/pubmed/fdv057

Cited by 42 publications

(42 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whilst effective treatments can reduce the risk of CHD, many interventions are not being implemented, and about half of patients with CHD in Europe still require more intensive blood pressure management (WHO ). The Irish Longitudinal Study on Ageing reports high incidence rates of hypertension with low levels of treatment and awareness in adults over fifty (Murphy et al., ). Prevention and treatment of dyslipidaemias should be considered within the broader framework of CHD prevention, in consultation with the patient (European Society of Cardiology, ).…”

Section: Introductionmentioning

confidence: 99%

“Heart disease never entered my head”: Women's understanding of coronary heart disease risk factors

Smith

Frazer

Hyde

et al. 2018

Journal of Clinical Nursing

View full text Add to dashboard Cite

This study demonstrates that primary and secondary prevention education initiatives are needed for CHD risk factor management and symptom interpretation. The implications of smoking on cardiovascular health need further dissemination. Efforts to support smoking cessation need to be strengthened and widely accessible. Primary care can have a key role to play in managing CHD risk and supporting women with positive risk factors.

show abstract

Section: Introductionmentioning

confidence: 99%

“Heart disease never entered my head”: Women's understanding of coronary heart disease risk factors

Smith

Frazer

Hyde

et al. 2018

Journal of Clinical Nursing

View full text Add to dashboard Cite

show abstract

“…However, today, 58.9% of the population are treated with BP-lowering medication. 42 Therefore, it would be of interest to see whether exercise still has some adjunctive effect in reducing BP in patients already treated with medication. Therefore, given the current limited and inconsistent results, we aimed in the present study (1) to investigate the acute effect of one single walking session at moderate intensity on PEH and (2) to test whether polymorphisms of the ACE gene contribute to the variation in PEH response in medicated patients.…”

Section: Introductionmentioning

confidence: 99%

ACE polymorphisms and the acute response of blood pressure to a walk in medicated hypertensive patients

Goessler

Cornelissen

Oliveira

et al. 2015

J Renin Angiotensin Aldosterone Syst

View full text Add to dashboard Cite

Hypothesis/Introduction: Polymorphisms of the angiotensin converting enzyme (ACE) gene can interfere with exercise-induced acute blood pressure (BP) reduction. This cross-over study investigated the acute effect of a single walk on BP and tested whether polymorphisms of the ACE gene might explain the variation in BP responses. Materials and methods: Thirty-four healthy medicated individuals were randomized to one control and one walking session at 60-75% of heart rate reserve. Subjects left the laboratory wearing an ambulatory BP monitor until waking the next morning. Results: Overall, systolic BP was somewhat lower following the walking session (p=.06), which could be attributed to a consistently lower systolic BP for 5 h after exercise (p-interaction<.04) compared with control rest. Similarly, II/ID individuals had a lower systolic BP (p-interaction=.02) and diastolic BP (p-interaction<.01) for 5 h after walking compared with control rest. Among DD individuals, a single walk did not induce a reduction in BP (p-interaction>.05). Conclusions: Our results showed that postexercise hypotension can occur after a walk at moderate intensity in carriers of the I allele; we were not able to demonstrate this in DD individuals. Our results suggest that genetic variation in the ACE gene might affect the BP response to exercise, although more research is needed to confirm these findings.

show abstract

“…For example, in Ireland, only 52% of those with hypertension aged ≥50yrs have their blood pressure controlled to target levels, a proportion not dissimilar to 46.5% of the adult hypertensive population in the U.S. [42,43] Any additional barriers to anti-hypertensive medication adherence may further worsen blood pressure control, and subsequently associated cardiovascular health outcomes. This is especially true for a population who is high risk, by virtue of their current treatment status.…”

Section: Discussionmentioning

confidence: 99%

The international generalisability of evidence for health policy: A cross country comparison of medication adherence following policy change

2017

View full text Add to dashboard Cite

The international generalisability of evidence for health policy: a cross country comparison of medication adherence following policy change.Health Policy http://dx.doi.org/10. 1016/j.healthpol.2016.10.009 This is a PDF Þle of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its Þnal form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. 1 Title Page TitleThe international generalisability of evidence for health policy: a cross country comparison of medication adherence following policy change Running title Conflicts of InterestSJS and HW have no conflicts of interest. At the time that the study was carried out, JMP received salary support from CVS Caremark for unrelated research on medication adherence. JMF received salary support from CVS Caremark and Merck for unrelated research on medication adherence. 2 KeywordsPharmaceutical policy, Cost sharing, Medication adherence, Generalisability Word count ~3,2003 Highlights  We addressed the question of how generalisable evidence for policy making is across health systems by using a case study of two similar copayment policies in two different health systems and assessing the impact of each policy on adherence.  Two similar copayment policies, in apparently similar health systems, did not invoke similar responses in adherence to medications. Nuanced differences between the health systems and the patients within them may affect differences in impact of policies. Before applying evidence from one health system to the another health system, critical questions of the local applicability of the evidence are key to maximising its' utility. 4 AbstractIntroduction of copayments for prescriptions may increase morbidity and mortality.

show abstract

Hypertension prevalence, awareness, treatment and control in the over 50s in Ireland: evidence from The Irish Longitudinal Study on Ageing

Cited by 42 publications

References 39 publications

“Heart disease never entered my head”: Women's understanding of coronary heart disease risk factors

“Heart disease never entered my head”: Women's understanding of coronary heart disease risk factors

ACE polymorphisms and the acute response of blood pressure to a walk in medicated hypertensive patients

The international generalisability of evidence for health policy: A cross country comparison of medication adherence following policy change

Contact Info

Product

Resources

About